-
Insilico Medicine Secures Revolving Loan Facility with HSBC to Boost Drug Discovery Pipeline
•
China-based artificial intelligence (AI) drug developer Insilico Medicine has announced the establishment of a Revolving Loan Facility of up to USD 100 million with HSBC, a leading global bank and financial services institution. This customized financing solution is designed to support the expansion of Insilico’s proprietary novel drug discovery pipeline…
-
Insilico Medicine and Seto Biopartner to Leverage AI in Synthetic Biology and Drug Discovery
•
Insilico Medicine has announced a strategic partnership with Seto Bio (SHE: 300583) to harness cutting-edge AI technology to explore and optimize key steps in the engineering transformation of biological systems, advancing synthetic biology research and innovative drug development. Established in 2014, Insilico Medicine has built over 30 proprietary drug pipeline…
-
Insilico Medicine’s AI-Generated Drug Candidate ISM001-055 Shows Positive Phase II Results in IPF Study
•
China-based artificial intelligence (AI) drug developer Insilico Medicine has reported initial positive data from its Phase IIa study for ISM001-055, an in-house generative AI-generated drug candidate for idiopathic pulmonary fibrosis (IPF). The molecule, which targets TNIK (Traf2- and NCK- interacting kinase), has shown a positive safety profile and dose-dependent lung…
-
Insilico Medicine Partners with Inimmune Corporation to Utilize AI for Immunotherapy Innovation
•
Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a strategic research collaboration agreement with Inimmune Corporation, a U.S. biotechnology firm specializing in immunotherapy and vaccine innovation. Under the terms of the agreement, Inimmune will utilize Insilico’s proprietary generative AI platform, Chemistry42, to accelerate the…
-
Insilico Medicine’s ISM6331 Earns FDA Orphan Drug Designation for Mesothelioma Treatment
•
Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has announced that it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its pipeline candidate ISM6331. This potential best-in-class candidate drug is designed to treat mesothelioma, a rare and…
-
AI-Powered Biotech Insilico Medicine Initiates Phase I Clinical Trial for Inflammatory Bowel Disease Drug
•
Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has announced that the first patient has been dosed in a Phase I clinical study for its candidate drug ISM5411. This follows the drug’s initial entry into clinical studies in Australia. ISM5411 is an orally administered…
-
Insilico Medicine’s ISM8207 Enters Phase I Clinical Trial for Lymphoma and Solid Tumors
•
China’s generative artificial intelligence (AI)-driven biotech firm, Insilico Medicine, has announced the first patient dosing in a Phase I clinical study for ISM8207, a potential first-in-class drug candidate co-developed with Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196). The open-label, multi-center Phase I study aims to evaluate the…
-
Insilico Medicine Partners with invoX Pharma to Boost AI-Driven Drug Discovery
•
China’s generative artificial intelligence (AI)-driven biotech firm Insilico Medicine has entered into a partnership with compatriot firm invoX Pharma, a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177). The collaboration aims to combine Insilico’s AI and computer-aided drug discovery expertise, including its proprietary PandaOmics target discovery engine, with invoX’s innovative drug…
-
AI-Driven Biotech Insilico Medicine Teams Up with Hutao Tech for Precision Medicine Robotics
•
Insilico Medicine, a China-based biotech company driven by generative artificial intelligence (AI), has entered into a partnership with Hutao Tech, a Beijing-based life science data specialist. The collaboration aims to combine Hutao’s market resources and industry expertise in life science data with Insilico’s AI drug development platform, Pharma AI, and…
-
Menarini’s Stemline Signs $500M+ License with Insilico for Cancer Drug Candidate
•
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics, has entered an exclusive license agreement with China’s Insilico Medicine to develop a KAT6A inhibitor originating from Insilico’s AI-driven platform. The candidate, targeted for hormone-sensitive cancers and other oncological indications, shows promise as a potent KAT6A inhibitor based on preclinical data. KAT6A,…
-
Insilico Medicine Launches Clinical Study for First-in-Class PHD Inhibitor ISM5411 in IBD
•
Insilico Medicine, a China-based biotech leveraging generative artificial intelligence (AI), has announced the initiation of a clinical study for its potential first-in-class PHD inhibitor, ISM5411, targeting inflammatory bowel disease (IBD). ISM5411 is an intestinal-restricted small-molecule inhibitor developed using Insilico’s Pharma.AI platform, featuring a novel molecular framework and a unique binding…
-
Exelixis Secures Global Rights to Develop Insilico Medicine’s USP1 Inhibitor ISM3091
•
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into an exclusive license agreement with US firm Exelixis Inc., (NASDAQ: EXEL), granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1. USP1 has been identified as a synthetic lethal target in the…
